US pharma major Merck (NYSE: MRK) has reported a Phase III success for Welireg (belzutifan) plus Keytruda (pembrolizumab) as ...
United Therapeutics has announced that its long-term pivotal Phase III ADVANCE OUTCOMES study met its primary endpoint, with ralinepag reducing the risk of a clinical worsening event by 55% compared ...
California-based immunotherapy company 3T Biosciences has appointed Rebeca Villarreal-Barragan as head of clinical operations ...
ESTEVE CDMO, the global pure-play contract development and manufacturing organization (CDMO) specializing in high-quality ...
French biotech OSE Immunotherapeutics (Euronext Paris: OSE) is accelerating a strategic reset, pausing development of OSE-230 and discontinuing certain early research programs to concentrate capital ...
Danish vaccine maker Bavarian Nordic announced today, that the board of directors has entered into an agreement with CEO, Paul Chaplin, who wishes to step down for personal reasons.
Chinese biotech Antengene (SEHK: 6996) has secured reimbursement in South Korea for Xpovio (selinexor) in combination with ...
February 2026 saw robust M&A activity across the pharmaceutical and biotechnology sectors, marked by several high-value ...
Iranian biopharma CinnaGen has secured European marketing authorization for Zandoriah (teriparatide), a biosimilar to Forsteo ...
Chinese biotech Innovent Biologics (HKEX: 01801) has secured approval from China’s National Medical Products Administration ...
Canada-based clinical-stage biotech Zymeworks ) and Royalty Pharma today announced an agreement for $250 million in funding ...
US pharma giant Pfizer has withdrawn its European application for a marketing authorization of Zumrad (sasanlimab) for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results